Characterization of a vertebrate neuromuscular junction that demonstrates selective resistance to botulinum toxin. (1/266)

Botulinum toxin blocks transmitter release by proceeding through a series of four steps: binding to cell surface receptors, penetration of the cell membrane by receptor-mediated endocytosis, penetration of the endosome membrane by pH-induced translocation, and intracellular proteolysis of substrates that govern exocytosis. Each of these steps is essential for toxin action on intact cells. Therefore, alterations in cell structure or cell function that impede any of these steps should confer resistance to toxin. In the present study, screening for susceptibility to four serotypes of botulinum toxin revealed that the cutaneous-pectoris nerve-muscle preparation of Rana pipiens is resistant to type B botulinum toxin. Resistance was demonstrated both by electrophysiologic techniques and by dye-staining techniques. In addition, resistance to serotype B was demonstrated at toxin concentrations that were 2 orders of magnitude higher than those associated with blockade produced by other serotypes. In experiments on broken cell preparations, type B toxin cleaved synaptobrevin from frog brain synaptosomes. However, the toxin did not bind to frog nerve membranes. These findings suggest that resistance is due to an absence of cell surface receptors for botulinum toxin type B. The fact that cutaneous-pectoris preparations were sensitive to other botulinum toxin serotypes (A, C, and D), as well as other neuromuscular blocking agents (alpha-latrotoxin, beta-bungarotoxin), indicates that botulinum toxin type B receptors are distinct.  (+info)

Omitting antagonism of neuromuscular block: effect on postoperative nausea and vomiting and risk of residual paralysis. A systematic review. (2/266)

We have estimated the effect of omitting antagonism of neuromuscular block on postoperative nausea and vomiting. A systematic search (MEDLINE, EMBASE, Biological Abstracts, Cochrane library, reference lists and hand searching; no language restriction, up to March 1998) was performed for relevant randomized controlled trials. In eight studies (1134 patients), antagonism with neostigmine or edrophonium was compared with spontaneous recovery after general anesthesia with pancuronium, vecuronium, mivacurium or tubocurarine. On combining neostigmine data, there was no evidence of an antiemetic effect when it was omitted. However, the highest incidence of emesis with neostigmine 1.5 mg was lower than the lowest incidence of emesis with 2.5 mg. Numbers-needed-to-treat to prevent emesis by omitting neostigmine compared with using it were consistently negative with 1.5 mg, and consistently positive (3-6) with 2.5 mg. There was a lack of evidence for edrophonium. In two studies, three patients with spontaneous recovery after mivacurium or vecuronium needed rescue anticholinesterase drugs because of clinically relevant muscle weakness (number-needed-to-harm, 30). Omitting neostigmine may have a clinically relevant antiemetic effect when high doses are used. Omitting antagonism, however, introduces a non-negligent risk of residual paralysis even with short-acting neuromuscular blocking agents.  (+info)

Rapid and reversible effects of activity on acetylcholine receptor density at the neuromuscular junction in vivo. (3/266)

Quantitative fluorescence imaging was used to study the regulation of acetylcholine receptor (AChR) number and density at neuromuscular junctions in living adult mice. At fully functional synapses, AChRs have a half-life of about 14 days. However, 2 hours after neurotransmission was blocked, the half-life of the AChRs was now less than a day; the rate was 25 times faster than before. Most of the lost receptors were not quickly replaced. Direct muscle stimulation or restoration of synaptic transmission inhibited this process. AChRs that were removed from nonfunctional synapses resided for hours in the perijunctional membrane before being locally internalized. Dispersed AChRs could also reaggregate at the junction once neurotransmission was restored. The rapid and reversible alterations in AChR density at the neuromuscular junction in vivo parallel changes thought to occur in the central nervous system at synapses undergoing potentiation and depression.  (+info)

Anaesthesia for strabismus surgery: a regional survey. (4/266)

An increase in the demand by local surgeons for neuromuscular block during strabismus surgery, and the forced duction test in particular, led us to review the literature and conduct a regional survey of anaesthetic techniques used. A questionnaire was distributed to 379 anaesthetists in the region and 264 responses were received. The results demonstrated that 55% of paediatric patients and 66% of adult patients may have been operated on under suboptimal conditions; residual tone may have been present in the extraocular muscles during forced duction testing and strabismus correction.  (+info)

Failure to prevent an anaphylactic reaction to a second neuromuscular blocking drug during anaesthesia. (5/266)

Skin testing is used widely to determine the drug responsible for an anaphylactic reaction during anaesthesia. When a neuromuscular blocking drug in incriminated as the cause of a reaction, it is usual for neuromuscular blocking drugs which do not produce positive skin tests to be considered safe for subsequent use during anaesthesia. We describe three patients in whom false negative skin tests led to a second severe anaphylactic reaction to another neuromuscular blocking drug.  (+info)

Comparison of the intubation conditions provided by rapacuronium (ORG 9487) or succinylcholine in humans during anesthesia with fentanyl and propofol. (6/266)

BACKGROUND: Currently, the only approved muscle relaxant with a rapid onset and short duration of action is succinylcholine, a drug with some undesirable effects. Rapacuronium is an investigational nondepolarizing relaxant that also has a rapid onset and short duration and consequently should be compared with succinylcholine in its ability to facilitate rapid tracheal intubation. METHODS: This prospective, randomized clinical trial involved 336 patients. Anesthesia was induced with fentanyl and propofol and either 1.5 mg/kg rapacuronium or 1.0 mg/kg succinylcholine. The goal was to accomplish tracheal intubation by 60 s after administration of the neuromuscular blocking drug. Endotracheal intubation was performed, and conditions were graded by a blinded investigator. Recovery of neuromuscular function was assessed by electromyography. RESULTS: Intubation conditions were evaluated in 236 patients. Intubation by 60 s after drug administration occurred in 100% of patients with rapacuronium and in 98% with succinylcholine. Intubation conditions were excellent or good in 87% of patients with rapacuronium and in 95% with succinylcholine (P < 0.05). The time (median and range) to the first recovery of the train-of-four response was 8.0 (2.8-20.0) min with rapacuronium and 5.7 (1.8-17.7) min with succinylcholine (P < 0.05). The overall incidence of adverse effects was similar with both drugs. CONCLUSIONS: A 1.5-mg/kg dose of rapacuronium effectively facilitates rapid tracheal intubation. It can be considered a valid alternative to 1.0 mg/kg succinylcholine for this purpose.  (+info)

Rapid vasodilation in response to a brief tetanic muscle contraction. (7/266)

To test the hypothesis that vasodilation occurs because of the release of a vasoactive substance after a brief muscle contraction and to determine whether acetylcholine spillover from the motor nerve is involved in contraction-induced hyperemia, tetanic muscle contractions were produced by sciatic nerve stimulation in anesthetized dogs (n = 16), instrumented with flow probes on both external iliac arteries. A 1-s stimulation of the sciatic nerve at 1. 5, 3, and 10 times motor threshold increased blood flow above baseline (P < 0.01) for 20, 25, and 30 s, respectively. Blood flow was significantly greater 1 s after the contraction ended for 3 and 10 x motor threshold (P < 0.01) and did not peak until 6-7 s after the contraction. The elevations in blood flow to a 1-s stimulation of the sciatic nerve and a 30-s train of stimulations were abolished by neuromuscular blockade (vecuronium). The delayed peak blood flow response and the prolonged hyperemia suggest that a vasoactive substance is rapidly released from the contracting skeletal muscle and can affect blood flow with removal of the mechanical constraint imposed by the contraction. In addition, acetylcholine spillover from the motor nerve is not responsible for the increase in blood flow in response to muscle contraction.  (+info)

Effects of non-depolarizing neuromuscular blocking agents on norepinephrine release from human atrial tissue obtained during cardiac surgery. (8/266)

We have studied the effect of non-depolarizing neuromuscular blocking agents, at concentrations present in serum during anaesthesia, on release of [3H]-norepinephrine ([3H]NE) from superfused atrial appendage obtained during cardiac surgery from 48 patients. Three of the neuromuscular blocking agents (pancuronium, gallamine and rocuronium), which are known to cause an increase in heart rate during anaesthesia, increased stimulation-evoked release of [3H]NE. In contrast, (+)tubocurarine and pipecuronium, neuromuscular blocking agents that do not cause tachycardia, did not affect release of NE. Org 9487 significantly enhanced release while SZ1677 was ineffective, even at concentrations higher than those expected after administration of a 2 x ED95 dose. Atropine enhanced release. These data suggest that the axon terminals of sympathetic nerves in human heart have muscarinic heteroreceptors whose activation by acetylcholine (ACh) released from the vagal nerve reduces release of NE. This action contributes to lowering of heart rate. Therefore, any neuromuscular blocking agent with antimuscarinic actions and capable of increasing the release of NE may produce tachycardia.  (+info)

... s, or Neuromuscular blocking agents (NMBAs), block transmission at the neuromuscular junction, ... A depolarizing neuromuscular blocking agent is a form of neuromuscular blocker that depolarizes the motor end plate. An example ... Ganglionic blocker Cholinergic blocking drugs "Dorlands Medical Dictionary:neuromuscular blocking agent".[permanent dead link] ... Pancuronium and some other neuromuscular blocking agents block M2-receptors and therefore affect the vagus nerve, leading to ...
US 5453510, Hill DA, Turner GL, "Neuromuscular blocking agents", issued 26 September 1995, assigned to Burroughs Wellcome Co ... is a bisbenzyltetrahydroisoquinolinium that has effect as a neuromuscular-blocking drug non-depolarizing neuromuscular-blocking ... "Biodegradable neuromuscular blocking agents. Part 6. Stereochemical studies on atracurium and related polyalkylene di-esters". ... risk to the use of cisatracurium in patients with liver or renal disease when compared with other neuromuscular-blocking agents ...
Neuromuscular-blocking agents can be classified in accordance to their duration of pharmacological action, defined as follows: ... Neuromuscular+blocking+agents at the U.S. National Library of Medicine Medical Subject Headings (MeSH) "Atracurium besilate". ... Stenlake JB, Waigh RD, Urwin J, Dewar GH, Hughes R, Chapple DJ (1981). "Biodegradable neuromuscular blocking agents. Part 3. ... Stenlake JB, Waigh RD, Dewar GH, Hughes R, Chapple DJ, Coker GG (1981). "Biodegradable neuromuscular blocking agents. Part 4. ...
Neuromuscular+blocking+agents at the U.S. National Library of Medicine Medical Subject Headings (MeSH) (Articles with short ... Taylor EP (1952). "Synthetic neuromuscular blocking agents. Part II. Bis(quaternary ammonium salts) derived from laudanosine". ... is a neuromuscular blocking drug or skeletal muscle relaxant in the category of non-depolarizing neuromuscular-blocking drugs, ... As with all clinically established (as well as experimental agents) with a non-depolarizing mechanism of action, its ...
Synthetic neuromuscular blocking agents. Part III. Miscellaneous quaternary ammonium salts". Journal of the Chemical Society ( ... "Effects of mescaline and some of its analogs on cholinergic neuromuscular transmission". Neuropharmacology. 32 (2): 169-174. ...
... is an aminosteroid neuromuscular blocking agent. Lees, P; Tavernor, WD (1969). "An investigation of the actions of ... the neuromuscular blocking agent, dipyrandium iodide, on cardiovascular and respiratory function in the horse". Research in ...
... (INN, BAN) (developmental code name NB-68) is an aminosteroid neuromuscular blocking agent which was never ... ISBN 978-3-642-45476-9. Kharkevich DA (6 December 2012). New Neuromuscular Blocking Agents: Basic and Applied Aspects. Springer ... 102-. ISBN 978-0-08-086264-4. Maclagan J (1976). "Competitive neuromuscular blocking drugs.". Neuromuscular Junction. Berlin, ... 647-. ISBN 978-1-4757-2085-3. Morton IK, Hall JM (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties ...
Cholinesterase Inhibitors & Other Pharmacologic Antagonists to Neuromuscular Blocking Agents.". Morgan & Mikhail's Clinical ... Methotrexate blocks the action of dihydrofolate reductase and thereby halts thymidine biosynthesis. This block of nucleotide ... An enzyme inhibitor is a molecule that binds to an enzyme and blocks its activity. Enzymes are proteins that speed up chemical ... Zhang L, He J, Bai L, Ruan S, Yang T, Luo Y (July 2021). "Ribosome-targeting antibacterial agents: Advances, challenges, and ...
... is an aminosteroid non-depolarizing neuromuscular blocking agent. Fitzal, S; Ilias, W; Kalina, K; Schwarz, S ... Neuromuscular blockers, All stub articles, Steroid stubs, Musculoskeletal system drug stubs). ... Foldes, FF; Steinbereithner, K (1982). "Neuromuscular and cardiovascular effects of Duador, a new short-acting nondepolarizing ...
DaxibotulinumtoxinA is an acetylcholine release inhibitor and neuromuscular blocking agent. Botulinum toxin is also used to ... In all cases, the toxin can then spread, blocking nerves and muscle function. In severe cases, the toxin can block nerves ... Botulinum toxin has been recognized as a potential agent for use in bioterrorism. It can be absorbed through the eyes, mucous ... University-based ophthalmologists in the US and Canada further refined the use of botulinum toxin as a therapeutic agent. By ...
Curare acts as a neuromuscular blocking agent that induces flaccid paralysis. This poison binds to the acetylcholine (ACh) ... This happens because C. botulinum produces a toxin that blocks the release of acetylcholine. Botulism toxin blocks the ... receptors on the muscle, blocking them from binding to ACh. As a result, ACh accumulates within the neuromuscular junction, but ... Some chemical warfare nerve agents such as VX can also cause complete flaccid paralysis. In some situations, prominently in ...
... is an aminosteroid neuromuscular blocking agent and antinicotinic alkaloid isolated from Malouetia spp. The ... "Pancuronium bromide and other steroidal neuromuscular blocking agents containing acetylcholine fragments". Journal of Medicinal ... Alauddin, M.; Caddy, B.; Lewis, J.J.; Martin-Smith, M.; Sugrue, M.F. (January 1965). "Non-depolarising neuromuscular blockade ... Neuromuscular blockers, Quaternary ammonium compounds, All stub articles, Steroid stubs, Musculoskeletal system drug stubs). ...
... (formerly marketed as Alloferin) is a neuromuscular blocking (NMB) agent, alternatively referred to as a ... Hughes R, Chapple DJ (1976). "Effects of Non-Depolarizing Neuromuscular Blocking Agents on Peripheral Autonomic Mechanisms in ... a very long acting neuromuscular blocking agent For a formal definition of the durations of actions associated with NMB agents ... "The Mode of Action of Quaternary Ammonium Type Neuromuscular Blocking Agents". Br. J. Anaesth. 26 (6): 394-398. doi:10.1093/bja ...
Hence, neuromuscular blocking agents (e.g. vecuronium bromide) would be used. Eventually, potassium chloride would be used to ... can block the acetylcholine receptors of the muscle cells in the neuromuscular junction to prevent respiratory muscles ... As such, lawsuits have been filed against the use of sodium thiopental and paralyzing agents in the execution. Thirdly, manual ... The drugs may involve barbiturate (e.g. sodium thiopental or midazolam). Then, paralyzing agents would be injected to paralyze ...
Buckett WR, Hewett CL, Savage DS (October 1973). "Pancuronium bromide and other steroidal neuromuscular blocking agents ... It competitively inhibits the nicotinic acetylcholine receptor at the neuromuscular junction by blocking the binding of ... "Steroidal monoquaternary ammonium salts with non-depolarizing neuromuscular blocking activity". The Journal of Pharmacy and ... It has slight vagolytic activity, causing an increase in heart rate, but no ganglioplegic (i.e., blocking ganglions) activity. ...
The neuromuscular blocking agents paralyze all of the skeletal muscles, most notably and importantly in the oropharynx, larynx ... Generally the patient will be manually ventilated for a short period of time before a neuromuscular blocking agent is ... However, the difference lies in the fact that the induction drug and neuromuscular blocking agent are administered in rapid ... Neostigmine - It can be used to reverse nondepolarizing neuromuscular blocking agents which cannot be reversed with Sugammadex ...
See neuromuscular blocking agents page for details on the mechanism of action. Nicotinic acetylcholine receptor Nicotinic ... These compounds are mainly used for peripheral muscle paralysis in surgery, the classical agent of this type being tubocurarine ... Antihypertensive agent stubs, Musculoskeletal system drug stubs, Nervous system drug stubs). ... but some centrally acting compounds such as bupropion, mecamylamine, and 18-methoxycoronaridine block nicotinic acetylcholine ...
Nondepolarizing neuromuscular blocking agents, such as vecuronium bromide: Neuromuscular blockade is potentiated. CNS ... or proper neuromuscular balance If the indication is a medical emergency, such as malignant hyperthermia, the only significant ...
... hypnotic and neuromuscular blocking agents, and tracheal intubation, as well as monitoring techniques that were nonexistent in ... Bowman WC, Webb SN (October 1972). "Neuromuscular blocking and ganglion blocking activities of some acetylcholine antagonists ... Maclagen J (1976). "Competitive Neuromuscular Blocking Drugs". In Zaimis E (ed.). Neuromuscular Junction. Handbook of ... a long-acting neuromuscular blocking agent". The Journal of Pharmacology and Experimental Therapeutics. 118 (4): 395-406. PMID ...
During anesthesia, neuromuscular blocking agents, antibiotics, and latex are the most common causes. The cause remains unknown ... The old radiocontrast agents caused reactions in 1% of cases, while the newer lower osmolar agents cause reactions in 0.04% of ... These include agents such as contrast medium, opioids, temperature (hot or cold), and vibration. Sulfites may cause reactions ... The frequency of a reaction to an agent partly depends on the frequency of its use and partly on its intrinsic properties. ...
Effects of frequency of stimulation on the paralyzing dose of neuromuscular blocking agents. J. Pharmacol. and Exper. Therap. ... Subcommittee on Chemotherapeutic Agents, National Multiple Sclerosis Society (1975-1980); Chairman, Sponsored Research Advisory ...
When neuromuscular blocking agents are administered, neuromuscular function of the patient must be monitored. Neuromuscular ... In anesthesia, neuromuscular blocking agents may be required to facilitate endotracheal intubation and provide optimal surgical ... Importantly, it is used to confirm adequacy of recovery after the administration of neuromuscular blocking agents. The response ... Neuromuscular monitoring is recommended when neuromuscular-blocking drugs have been part of the general anesthesia and the ...
From the 1950s through to the 1970s, the present-day concept of a neuromuscular blocking agent with a rapid onset and an ultra- ... depolarizing neuromuscular-blocking drug or skeletal muscle relaxant in the category of non-depolarizing neuromuscular-blocking ... Mivacurium is a biodegradable neuromuscular blocking agent owing to its degradation by plasma cholinesterases - the esterases ... is a complete misnomer for all clinically introduced and currently used neuromuscular blocking agents in this class because ...
Neuromuscular-blocking agents: Amphorectin B-induced hypokalemia may potentiate the effects of certain paralytic agents. ... This is amphotericin B's primary effect as an antifungal agent. It has been found that the amphotericin B/ergosterol ... O'Keeffe J, Doyle S, Kavanagh K (December 2003). "Exposure of the yeast Candida albicans to the anti-neoplastic agent ... European Committee on Antimicrobial Susceptibility Testing (2015-11-16). "Antifungal Agents, Breakpoint tables for ...
Neuromuscular+blocking+agents at the U.S. National Library of Medicine Medical Subject Headings (MeSH) (Articles with short ... As with other neuromuscular-blocking agents, candocuronium preferentially antagonizes competitively the nicotinic subtype of ... The discovery of candocuronium led to numerous related neuromuscular-blocking agents with short durations of action but also ... Marshall IG, Paul D, Singh H (May 1973). "The neuromuscular and other blocking actions of 4,17a-dimethyl-4,17a-diaza-d-homo-5 - ...
General anesthetic agents, opioids, and neuromuscular-blocking drugs may diminish or even abolish the respiratory drive. ... followed by the sequential administration of an intravenous sleep-inducing agent and a rapidly acting neuromuscular-blocking ... intubation is usually performed after administration of general anesthesia and a neuromuscular-blocking drug. It can, however, ... Spontaneous ventilation has been traditionally performed with an inhalational agent (i.e. gas induction or inhalational ...
They are neuromuscular blocking agents, acting as competitive antagonists of the nicotinic acetylcholine receptor (nAChR), and ... Benzylisoquinolines, such as atracurium and tubocurarine, the other major group of neuromuscular blocking agents Ted Lin; Tim ... block the signaling of acetylcholine in the nervous system. These drugs include candocuronium iodide (chandonium iodide), ...
... a phenomenon of recurrence of neuromuscular block, may occur where the reversal agents wear off before a neuromuscular blocking ... Sugammadex has been shown to have affinity for two other aminosteroid neuromuscular blocking agents, vecuronium and pancuronium ... This is very unusual with all but the longest acting neuromuscular blocking drugs (such as gallamine, pancuronium or ... "FDA approves Bridion to reverse effects of neuromuscular blocking drugs used during surgery" (Press release). Food and Drug ...
... and the person's cessation of spontaneous respiration is not caused by neuromuscular blocking agents or other drugs. Criteria ... The police will provide a hearse to send the body to the Centre for Forensic Medicine (CFM) Mortuary at Block 9 of the ... The site includes a columbarium built in several phases, comprising niches arranged in numbered blocks which either feature ...
... should not be used with neuromuscular blocking agents, as they can increase muscle weakness and paralysis. Amikacin ... neuromuscular blocking agents, or large doses of blood that contains citrate as an anticoagulant. Potent diuretics not only ... Amikacin works by blocking the function of the bacteria's 30S ribosomal subunit, making it unable to produce proteins. Amikacin ... Resistance to amikacin and kanamycin in Mycobacterium, the causative agent of tuberculosis, is due to a mutation in the rrs ...
... does pretreatment with a competitive neuromuscular blocking agent improve outcome? A literature review ... does pretreatment with a competitive neuromuscular blocking agent improve outcome? A literature review ... of patients with acute brain injury and whether pretreatment with a defasciculating dose of competitive neuromuscular blocker ... could find no studies that investigated the issue of pretreatment with defasciculating doses of competitive neuromuscular ...
Stability of Diluted Neuromuscular Blocking Agents Utilized in Perioperative Hypersensitivity Evaluation. Allergy. Vol.73(12). ...
keywords = "anaphylaxis, hypersensitivity, neuromuscular blocking agent, obesity, pholcodine, rocuronium",. author = "Sadleir ... Background: The observation that patients presenting for bariatric surgery had a high incidence of neuromuscular blocking agent ... Dive into the research topics of Relationship of perioperative anaphylaxis to neuromuscular blocking agents, obesity, and ... Relationship of perioperative anaphylaxis to neuromuscular blocking agents, obesity, and pholcodine consumption: a case-control ...
Abstract 11: Intubation without neuromuscular blocking agents: risk of trach. EMA 2020 May26 Chapters ... Abstract 11: Intubation without neuromuscular blocking agents: risk of trach2:50 ... Abstract 20: Subcutaneous digital nerve block efficacy according to location3:57 ...
Impact of high- versus low-dose neuromuscular blocking agent administration on unplanned 30-day readmission rates in ...
Neuromuscular Blocking Agents are required in addition to normal sedative/anaesthetic protocols in order to prevent all ... Use of Neuromuscular blocking agents webinar from Linnaeus Veterinary Group on Vimeo. ...
BLOCKING AGENTS PROF V K BHATIA DEPT OF ANAESTHESIOLOGY KGMU ... NEUROMUSCULAR JUNCTION PHYSIOLOGY & BLOCKING AGENTS PROF V K ... Reversal of NM Block n Clinical practice: n n Rule of thumb: n n n if no evidence block + 4 half-lives: omit reversal if still ... Neuromuscular junction (example of chemical synapse) n n n Neuromuscular junction : the synapse between motor neuron and muscle ... n non-depolarizing block easily reversible if 2 twitches n residual block: incidence with intermediate rx Monitoring + Reversal ...
7.3 Neuromuscular Blocking Agents. Clindamycin has been shown to have neuromuscular blocking properties that may enhance the ... 7.3 Neuromuscular Blocking Agents 8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy 8.3 Nursing Mothers 8.4 Pediatric Use 8.5 ... action of other neuromuscular blocking agents. Therefore, ZIANA Gel should be used with caution in patients receiving such ... Antiperistaltic agents such as opiates and diphenoxylate with atropine may prolong and/or worsen severe colitis. Severe colitis ...
7.2 Neuromuscular Blocking Agents 7.3 Concomitant use with N 2O 8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy 8.2 Lactation 8.4 ... Dosage reduction of neuromuscular blocking agents during induction of anesthesia may result in delayed onset of conditions ... 7.2 Neuromuscular Blocking Agents. Anesthetic concentrations of desflurane at equilibrium (administered for 15 or more minutes ... Desflurane, USP, Liquid for Inhalation also decreases the doses of neuromuscular blocking agents required [See Drug ...
Neuromuscular blocking agent. Reversal agent. Outcomes with sugammadex. Togioka et al., 2020 [46]. RCT. Patients aged ≥ 70 yr. ... Choice of neuromuscular block reversal agent to reduce postoperative pulmonary complications. Reversal agent and pulmonary ... Keywords: Anticholinesterases; Neuromuscular blocking agents; Postoperative complications; Residual neuromuscular blockade; ... Choice of neuromuscular block reversal agent to reduce postoperative pulmonary complications. Anesth Pain Med. 2022;17(2):121- ...
Neuromuscular-blocking drugs, or Neuromuscular blocking agents (NMBAs), block transmission at the neuromuscular junction, ... A depolarizing neuromuscular blocking agent is a form of neuromuscular blocker that depolarizes the motor end plate. An example ... Ganglionic blocker Cholinergic blocking drugs "Dorlands Medical Dictionary:neuromuscular blocking agent".[permanent dead link] ... Pancuronium and some other neuromuscular blocking agents block M2-receptors and therefore affect the vagus nerve, leading to ...
Neuromuscular blocking agents (NMBAs) are part of the three elements of general anaesthesia (sedation, analgesia, and muscle ...
... early administration of a neuromuscular blocking agent improved the adjusted 90-day survival and increased the time off the ... We evaluated clinical outcomes after 2 days of therapy with neuromuscular blocking agents in patients with early, severe ARDS. ... Conclusions: In patients with severe ARDS, early administration of a neuromuscular blocking agent improved the adjusted 90-day ... neuromuscular blocking agents may improve oxygenation and decrease ventilator-induced lung injury but may also cause muscle ...
The pharmacology of new short-acting nondepolarizing ester neuromuscular blocking agents: clinical implications.. ... The pharmacology of new short-acting nondepolarizing ester neuromuscular blocking agents: clinical implications.. ... Neuromuscular Nondepolarizing Agents, Pentobarbital, Quaternary Ammonium Compounds, Succinylcholine, Tubocurarine. Alternate ...
Transient Cross-Resistance to Neuromuscular Blocking Agents in a Patient with Tetanus Jan-Wei Chiu, M.D.; Jan-Wei Chiu, M.D. ... RESISTANCE to nondepolarizing neuromuscular blocking agents (NMBAs) occurs in many clinical diseases and drug interactions. ... Short-acting neuromuscular blocking agent (NMBA), mivacurium (11 mg), was administered to facilitate tracheal intubation. ... Transient Cross-Resistance to Neuromuscular Blocking Agents in a Patient with Tetanus. Anesthesiology 2003; 98:579-581 doi: ...
A vagolytic action of neuromuscular blocking agents at the pacemaker of the isolated guinea pig atrium.. Son, S L; Waud, D R. ... To examine the basis of tachycardia seen clinically with some neuromuscular blocking agents, the potencies of d-tubocurarine, ... Comparison with atropine indicated that the vagolytic action of the neuromuscular blocking agents was not attributable to ... These ED50 values were compared with the respective potency values of these agents at the motor endplate. This comparison ...
Neuromuscular Blocking Agents. Clinical data and animal studies suggest that verapamil may potentiate the activity of ... It may be necessary to decrease the dose of verapamil and/or the dose of the neuromuscular blocking agent when the drugs are ... and that verapamil prolongs recovery from the neuromuscular blocking agent vecuronium and causes a worsening of myasthenia ... Drug classes: Calcium channel blocking agents, Group IV antiarrhythmics. Medically reviewed by Drugs.com. Last updated on Feb ...
The Use of In-vitro Technique in the Development of New Neuromuscular Blocking Agents Joannes H. Karis, M.D.; Joannes H. Karis ... The Use of In-vitro Technique in the Development of New Neuromuscular Blocking Agents. Anesthesiology 1968; 29:199 doi: https ... Mode of Action of Diethyl Ether in Blocking Neuromuscular Transmission Anesthesiology (January 1966) ... The Effect of Volatile Anesthetic Agents on Neuromuscular Transmission Anesthesiology (January 1967) ...
Prone positioning has been indisputably shown to improve oxygenation in patients with ARDS [23]. Neuromuscular blocking agents ... Off all adjunctive treatments for refractory hypoxemia, only neuromuscular blocking agents were more often used in obese ... We also collected adjunctive strategies including the use of neuromuscular blocking agents and extracorporeal membrane ... This may increase patient-ventilator asynchronies, for which clinicians could prescribe neuromuscular blocking agents. ...
Intermediate-Acting Nondepolarizing Neuromuscular Blocking Agents and Risk of Postoperative 30-Day Morbidity and Mortality, and ... BACKGROUND: Nondepolarizing neuromuscular blocking drugs (NNMBDs) are commonly used as an adjunct to general anesthesia. ...
A national survey of critical care nurses practices related to administration of neuromuscular blocking agents JG Foster; JG ... RESULTS: Seventy-five percent of respondents reported long-term use of neuromuscular blocking agents in critically ill patients ... Of these, 246 surveys (51%) were returned and analyzed to determine use of neuromuscular blocking agents, peripheral nerve ... BACKGROUND: Recommendations on use of neuromuscular blocking agents include using peripheral nerve stimulators to monitor depth ...
Neuromuscular blocking agents (eg, succinylcholine, vecuronium bromide). * Immune enhancement (eg, tetanus toxoid adsorbed or ...
Neuromuscular blocking agents As with other inhalational anesthetic agents, sevoflurane affects both the intensity and duration ... Dosage reduction of neuromuscular blocking agents during induction of anesthesia may result in delayed onset of conditions ... suitable for endotracheal intubation or inadequate muscle relaxation because potentiation of neuromuscular blocking agents is ... When used to supplement alfentanil-N2O anesthesia, sevoflurane potentiates neuromuscular block induced with pancuronium, ...
It may potentiate the effect of depolarizing and competitive neuromuscular blocking agents. The clearance of lithium can be ... Abrupt withdrawal of beta-blocking agents may adversely affect the heart rate and blood pressure and may precipitate MI. ... Psychotropic agents. Psychotropic agents demand close attention in the perioperative period. Their complex effects on ... These agents may be used for the allergic patient or in preparing a patient for exposure to an allergenic trigger, such as ...
Zlotos DP (2005) Recent advances in neuromuscular blocking agents. Mini-Rev Med Chem 5:595-606. https://doi.org/10.2174/ ... Patel SS, Savjani JK (2015) Systematic review of plant steroids as potential anti-inflammatory agents: current status and ... Studies on novel D-ring substituted steroidal pyrazolines as potential anticancer agents. Steroids 75:805-809. https://doi.org/ ...
Chapter 11 NEUROMUSCULAR BLOCKING AND REVERSAL AGENTS. Chapter 12 ANESTHETIC NEUROTOXICITY. Section III PREOPERATIVE ... Chapter 18 PERIPHERAL NERVE BLOCKS. Chapter 19 PATIENT POSITIONING AND ASSOCIATED RISKS. Chapter 20 ANESTHETIC MONITORING. ...
Non-depolarizing Neuromuscular Blocking Agent *Structurally similar to Pancuronium. *Same steroid nucleus ... Paralytic Agents do not alter Level of Consciousness. *Must be used with sedation and analgesia ...
It also provides neuromuscular blocking agents for use in surgery; antibacterial products for skin and skin structure ... NYSE: MRK) offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, ...
Neuromuscular Blocking Agents *Local Anesthetics *Drug Interactions. Pre-Anesthetic Evaluation and Preparation. *Preoperative ... Anesthetic Agents, Adjuvants, and Drug Interaction. *Inhaled Anesthetics *Intravenous Anesthetics *Opioids * ...
Induction Agents. •Opiates. •Neuromuscular Blocking Agents. •Anticholinesterase Agents. •Selective Muscle Relaxant Binding ... a-Receptor Blocking Agents. •ß-Adrenergic Blocking Agents. •Bronchodilators. •Calcium Channel Blockers. •Antihypertensive ... However, blocking some types may impact your experience of our site and the services we are able to offer. See the different ... You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These ...
  • In clinical use, neuromuscular block is used adjunctively to anesthesia to produce paralysis, firstly to paralyze the vocal cords, and permit endotracheal intubation, and secondly to optimize the surgical field by inhibiting spontaneous ventilation, and causing relaxation of skeletal muscles. (wikipedia.org)
  • as a primary anesthetic agent for the induction of anesthesia in patients undergoing general surgery in which endotracheal intubation and mechanical ventilation are required. (nih.gov)
  • This medication is a neuromuscular-blocking agent, used as an adjuvant in anesthesia. (medindia.net)
  • Neuromuscular blockade is a pharmacological adjunct for anesthesia and for surgical interventions. (aacnjournals.org)
  • If an operation is particularly complex or requires a long anesthesia time, residual neuromuscular blockade can contribute to longer stays in the intensive care unit and more hours of mechanical ventilation. (aacnjournals.org)
  • Surgery, anesthesia, and other interventions in critical care are facilitated by the use of nondepolarizing neuromuscular blocking agents (NMBAs). (aacnjournals.org)
  • These drugs fall into two groups: Non-depolarizing blocking agents: These agents constitute the majority of the clinically relevant neuromuscular blockers. (wikipedia.org)
  • SA Health has updated its APINCH list to include some psychotropic medicines, epidural and intrathecal medicines and neuromuscular blockers. (sa.gov.au)
  • They can be of two types, competitive, stabilizing blockers (NEUROMUSCULAR NONDEPOLARIZING AGENTS) or noncompetitive, depolarizing agents (NEUROMUSCULAR DEPOLARIZING AGENTS). (bvsalud.org)
  • Neuromuscular blockers can facilitate ease of instrumentation and reduce complications associated with intubation. (aacnjournals.org)
  • In humans, administration of the drugs is not without risk and may result in accidental awareness under general anaesthesia and postoperative residual neuromuscular blockade. (awionline.org)
  • They also revealed a low rate of neuromuscular monitoring (38%) and, correspondingly, a very high incidence of postoperative residual neuromuscular blockade (RNMB) and associated complications. (hindawi.com)
  • An undesirable sequela of these agents is residual neuromuscular blockade. (aacnjournals.org)
  • Residual neuromuscular blockade is linked to aspiration, diminished response to hypoxia, and obstruction of the upper airway that may occur soon after extubation. (aacnjournals.org)
  • 2 , 3 However, these medications are also associated with the risk for residual neuromuscular blockade (RNMB) after surgery (also termed postoperative residual curarization or PORC). (aacnjournals.org)
  • OBJECTIVE: To update the 2002 version of ""Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient. (bvsalud.org)
  • Neuromuscular-blocking drugs, or Neuromuscular blocking agents (NMBAs), block transmission at the neuromuscular junction, causing paralysis of the affected skeletal muscles. (wikipedia.org)
  • 2 , 3 To manage and assess patients who received NMBAs during surgery or other procedures requires nurses to understand the current evidence on potential complications associated with these agents. (aacnjournals.org)
  • NMBAs blunt or abolish the neuromuscular protective reflexes of coughing, gagging, and blinking. (aacnjournals.org)
  • Why using Neuromuscular Blocking Agents (NMBAs)? (usach.cl)
  • Drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. (bvsalud.org)
  • 2022. Comparison of the neuromuscular effects of two infusion rates of rocuronium in anesthetized pigs. (awionline.org)
  • The two teens were treated with the neuromuscular blocking agent rocuronium because of symptom severity, and the two adults received pralidoxime because of the initial suspicion of possible organophosphate toxicity. (cdc.gov)
  • These agents inhibit the transmission of nerve impulses at the neuromuscular junction of skeletal muscle and/or autonomic ganglia. (medscape.com)
  • OnabotulinumtoxinA prevents calcium-dependent release of acetylcholine and produces a state of denervation at the neuromuscular junction and postganglionic sympathetic cholinergic nerves in the sweat glands. (medscape.com)
  • Myasthenia gravis (MG) is an autoimmune neuromuscular disorder which is characterized by presence of antibodies against acetylcholine receptors (AChRs) or other proteins of the postsynaptic membrane resulting in damage to postsynaptic membrane, decreased number of AChRs or blocking of the receptors by autoantibodies. (nih.gov)
  • Muscle relaxants inhibit neuron transmission to muscle by blocking the nicotinic acetylcholine receptor. (wikipedia.org)
  • Describe how cholinesterase inhibitors, including organophosphorus compounds ( e.g., pesticides, nerve agents) and carbamates block the ability of acetylcholinesterase to break down acetylcholine. (cdc.gov)
  • Acetylcholinesterase inhibitors (which, for brevity, we will refer to as cholinesterase inhibitors) are chemicals whose primary toxic effect is to block the normal breakdown of the neurotransmitter, acetylcholine . (cdc.gov)
  • They do this by occupying and blocking the site where the neurotransmitter, acetylcholine , attaches to the enzyme, acetylcholinesterase . (cdc.gov)
  • With toxic doses, the result is that excessive levels of the acetylcholine build up in the synapses and neuromuscular junctions and glands. (cdc.gov)
  • A neuromuscular non-depolarizing agent is a form of neuromuscular blocker that does not depolarize the motor end plate. (wikipedia.org)
  • The ultrashort-acting neuromuscular blocker,gantacurium, and other fumarates rapidly combine with L-cysteine in vitro to form less active degrada-tion products (adducts). (brainkart.com)
  • It is also advantageous in cases where intubation is necessary but neuromuscular block is not required to facilitate surgical access 1, 2 . (ijpsr.com)
  • This presentation covers how to manage neuromuscular blocking agent (NMBA) shortages. (sccm.org)
  • Two previously published audits [ 1 , 2 ] comparing the "pre-" and "post-"Sugammadex practice of neuromuscular blocking agent (NMBA) use and reversal in 2011 identified an approximate 50% decline in the use of neostigmine since introduction of Sugammadex. (hindawi.com)
  • This project aimed to gather information about the practice of neuromuscular monitoring, NMBA, and reversal use and the incidence of RNMB. (hindawi.com)
  • Erythromycin is a bacteriostatic agent that inhibits protein synthesis by binding to the 50S subunit of bacterial ribosomes. (medscape.com)
  • Tetracycline is a bacteriostatic agent that inhibits protein synthesis. (medscape.com)
  • Vancomycin is a bactericidal agent that inhibits cell wall and RNA synthesis. (medscape.com)
  • Neuromuscular blocking drugs are often classified into two broad classes: Pachycurares, which are bulky molecules with nondepolarizing activity Leptocurares, which are thin and flexible molecules that tend to have depolarizing activity. (wikipedia.org)
  • They all exhibit a depolarizing block. (wikipedia.org)
  • Most of the agents in this category would also be classified as non-depolarizing. (wikipedia.org)
  • Depolarizing blocking agents: These agents act by depolarizing the sarcolemma of the skeletal muscle fiber. (wikipedia.org)
  • Pyrantel pamoate is a depolarizing neuromuscular blocking agent. (medscape.com)
  • Fumarates: unique nondepolarizing neuromuscular blocking agents that are antagonized by cysteine. (cornell.edu)
  • We found that, in the 2.5 years since introduction of Sugammadex, more anesthetists (69.5 versus 38%) utilized neuromuscular monitoring, and aminosteroidal neuromuscular blocking agents were used in 94.3% of cases (versus 77% in 2011). (hindawi.com)
  • Benzoyl peroxide is a medication that has antibacterial effects and is a peeling agent . (medbroadcast.com)
  • Clostridium difficile -associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including clindamycin, and may range in severity from mild diarrhea to fatal colitis. (nih.gov)
  • Clindamycin is a bacteriostatic agent that binds to the 50S ribosomal subunit. (medscape.com)
  • Note: The actual clinical manifestations of an exposure to a nerve agent or an organophosphate pesticide may be more variable than the syndrome described in this document. (cdc.gov)
  • Two departmental audits (26-page online survey and 1-week in-theatre snapshot audit) were undertaken to investigate the change of beliefs and clinical practice related to the use of neuromuscular blocking agents at the Royal Perth Hospital since this introduction. (hindawi.com)
  • They act by competitively blocking the binding of ACh to its receptors, and in some cases, they also directly block the ionotropic activity of the ACh receptors. (wikipedia.org)
  • Atenolol blocks beta-1 receptors, which are present on the heart. (medindia.net)
  • Among all inhalation agents, Sevoflurane has a low blood gas partition coefficient, and the relative absence of pungency, the non-irritant effect on the airways, less hypotension 3 , a pleasant smell makes successful rapid and smooth induction inhalation induction without using neuromuscular blocking agents 4 . (ijpsr.com)
  • For example, inhalation of a nerve agent or an OP pesticide leads to a quicker onset of poisoning with more severe symptoms when compared to with dermal exposure s, given the same amount of agent. (cdc.gov)
  • Nerve agents are chemical warfare agents that have the same mechanism of action as OP organophosphate pesticides insecticides. (cdc.gov)
  • The amount and route of exposure to the nerve agent or OP pesticide, the type of nerve agent or pesticide, and the premorbid condition of the person exposed person will contribute to the time of onset and the severity of illness. (cdc.gov)
  • Manage with neuromuscular blocking agent. (nih.gov)
  • Normal sinus rhythm is usually not affected, but in patients with sick sinus syndrome, CALAN may interfere with sinus-node impulse generation and may induce sinus arrest or sinoatrial block. (nih.gov)
  • Although tetracyclines are an alternative in patients who have a history of serious allergic reactions to penicillin or metronidazole (eg, urticaria, anaphylaxis), strong consideration should be given to desensitizing the patient to penicillin before resorting to alternative agents. (medscape.com)
  • ASCO does not consider metoclopramide an appropriate first-line antiemetic for any group of patients receiving chemotherapy of high emetic risk and states that this drug should be reserved for patients unable to tolerate or refractory to first-line agents (i.e., a type 3 serotonin [5-HT 3 ] receptor antagonist [e.g., dolasetron, granisetron, ondansetron, palonosetron] with dexamethasone and aprepitant). (drugs.com)
  • Mebendazole causes worm death by selectively and irreversibly blocking uptake of glucose and other nutrients in susceptible adult intestine where helminths dwell. (medscape.com)
  • The increasing use of neuromuscular blocking agents, also called muscle relaxants, significantly changed this practice. (woodlibrarymuseum.org)
  • Used parenterally in high doses for the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy including cisplatin alone or in combination with other antineoplastic agents. (drugs.com)
  • Prevention of nausea and vomiting associated with other antineoplastic agents (e.g., cyclophosphamide, dacarbazine, doxorubicin, methotrexate) and with cancer chemotherapy regimens that do not include cisplatin. (drugs.com)
  • An antineoplastic agent used in the treatment of malignant melanoma and sarcoma. (theodora.com)
  • Drugs used to treat muscle spasm, rigidity, and tetanic seizures include sedative-hypnotic agents, general anesthetics, centrally acting muscle relaxants, and neuromuscular blocking agents. (medscape.com)
  • Acenocoumarol is a blood thinner agent prescribed to treat or prevent the formation of blood clots or thrombus in the blood vessels helps by dissolving the blood clots and reducing the complication of thromboembolic disorders. (medindia.net)
  • It blocks the action of cyclo-oxygenase responsible for causing pain and inflammation. (medindia.net)
  • In surgery, it was hailed as a superior preanesthetic agent, with fewer and milder side effects than those of older barbiturates. (woodlibrarymuseum.org)
  • Because the appropriate dose of neuromuscular-blocking drug may paralyze muscles required for breathing (i.e., the diaphragm), mechanical ventilation should be available to maintain adequate respiration. (wikipedia.org)
  • Novel NMB agents In recent years much research has been devoted to new types of quaternary ammonium muscle relaxants. (wikipedia.org)
  • Benzodiazepines are the most effective primary agents for muscle spasm prevention and work by enhancing gamma-aminobutyric acid (GABA) inhibition. (medscape.com)
  • The purpose of this document is to enable health care workers and public health officials to recognize an unknown or suspected exposure to a nerve agent or an organophosphate (OP) pesticide. (cdc.gov)
  • The following is a more comprehensive list of signs and symptoms that may be encountered in a person exposed to a nerve agent or OP pesticide. (cdc.gov)
  • Plasma or RBC cholinesterase may be disproportionately inhibited depending on the particular nerve agent, amount of exposure and time interval since exposure. (cdc.gov)
  • Figure 2 below shows how a cholinesterase inhibitor (in this case, a nerve agent) attaches to the serine hydroxyl group on acetylcholinesterase. (cdc.gov)
  • Parasite biochemical pathways are sufficiently different from the human host to allow selective interference by chemotherapeutic agents in relatively small doses. (medscape.com)

No images available that match "neuromuscular blocking agents"